TABLE 3.
Pediatric Mortality Rates After HAART in RLCs and DCs
| Country | N | Time | Lost to Follow-up, % | Mortality, % | DPCY |
|---|---|---|---|---|---|
| RLCs | |||||
| Burkina Faso (Hien et al19) | 52 | 12 mo | 2 | 3.8 | 3.9 |
| Kenya (Nyandiko et al22) | 279 | 34 mo (median) | 11 | 6.8 | 2.5 |
| Kenya (Song et al23) | 29 | 15 mo | 3 | 0 | 0 |
| Kenya (Van Winghem et al24) | 648 | 12 mo | NR | 1.1 | 1.1 |
| Kenya (Wamalwa et al25) | 67 | 6 mo | NR | 9.0 | 18.8 |
| Lesotho (Cohen et al28) | 283 | 12 mo | 2 | 5.0 | 5.1 |
| Lesotho (Leyenaar et al27) | 284 | 14 mo | 1 | 6.3 | 5.5 |
| Malawi A16 | 436 | 6 mo | 11 | 5.0 | 10.3 |
| Malawi B16 | 233 | 12 mo | 15 | 13.0 | 13.9 |
| Mozambique (Marazzi et al31) | 297 | 6 mo | NR | 8.4 | 17.5 |
| Rwanda (van Griensven et al33) | 315 | 24 mo | 4 | 2.5 | 1.4a |
| South Africa (Barth et al35) | 66 | 12 mo | 17 | 9.0 | 9.5 |
| South Africa (Eley36) | 407 | 12 mo | NR | 15.4 | 16.8 |
| South Africa (Jaspan et al37) | 391 | 12 mo | 2 | 6.9 | 7.2 |
| South Africa (Jooste et al38) | 100 | 6 mo | 3 | 9.0 | 18.8 |
| South Africa (Smit et al39) | 615 | 12 mo | NR | 10.2 | 10.8 |
| Tanzania (Bl+è et al40) | 59 | 12 mo | 0 | 0 | 0 |
| Uganda (Kamya et al41) | 250 | 12 mo | 1 | 5.2 | 5.3 |
| Zambia (Bolton-Moore et al42) | 2938 | 36 mo | 13 | 8.3 | 6.6a |
| Zambia (Walker et al44) | 93 | 24 mo | NR | 6.5 | 3.3 |
| Africa mean | n/a | n/a | NR | 7.4 ± 0.6b | 7.5 ± 4.9b |
| Cambodia (Myung et al13) | 117 | 6 mo | NR | 18.8 | 41.5 |
| Cambodia (Janssens et al45) | 212 | 12 mo | 2 | 6.0 | 6.2 |
| India (Rajasekaran et al47) | 295 | 10 mo (median) | 2 | 8.1 | 10.2 |
| Thailand (Puthanakit et al51) | 192 | 48 wk | NR | 6.7 | 2.8a |
| Asia/Eastern Europe mean | n/a | n/a | NR | 8.8 ± <0.1b | 11.9 ± 9.2b |
| Brazil (Romanelli et al52) | 43 | 34 mo (median) | 9.3 | 0 | 0 |
| Haiti (George et al12) | 236 | 12 mo | 10 | 9.0 | 9.9 |
| South America/Caribbean mean | n/a | n/a | NR | 7.6 ± 0.1b | 8.4 ± 16.4b |
| DCs | |||||
| PENTA82 | 103 | 48 wk | NR | 1.0 | 1.1 |
| Denmark (Bracher et al69)c | 49 | 108 mo | NR | 2.0 | 0.4a |
| France (Thuret et al71)c | 22 | 16 mo (median) | NR | 0 | 0 |
| Netherlands (Fraaij et al73)c | 31 | 48 mo | 16 | 3.1 | 0.4 |
| Switzerland (Rudin et al79)c | 133 | 66 mo | 1 | 3.8 | 1.1a |
| US (McKinney et al59) | 27 | 24 mo | NR | 0 | 0 |
| US (Patel et al61)c | 866 | 70 mo (median) | NR | 1.4 | 0.9a |
| Mean | n/a | n/a | NR | 1.6 ± 0.2b | 0.9 ± 1.2b |
NR indicates not reported; n/a, not applicable.
a
Directly reported number of child-years of follow-up.
b
95% confidence intervals for weighted mean.
c
Included mono/dual ART-experienced patients.